6 citations
,
March 2022 in “International journal of molecular sciences” Natural skincare products may help reduce sun damage and support the skin's daily cycle.
3 citations
,
February 2024 in “International journal of molecular sciences” Hesperidin from orange peels is a promising natural ingredient for skincare due to its multiple beneficial properties.
2 citations
,
January 2025 in “International Journal of Molecular Sciences” Chitosan-encapsulated Cordyceps militaris reduces lung cell damage from pollution.
1 citations
,
October 2025 in “International Journal of Molecular Sciences” Natural compounds may help treat advanced papillary thyroid cancer by targeting specific molecular pathways.
1 citations
,
December 2023 in “Biomolecules” Regulating cell death in hair follicles can help prevent hair loss and promote hair growth.
1 citations
,
September 2022 in “Molecules” Fructus Malvae may help with diabetes, tumors, and hair loss due to its various active compounds.
March 2026 in “Pharmaceutics” Plant-derived nanovesicles show promise in cancer treatment but need standardized preparation.
August 2025 in “International Journal for Vitamin and Nutrition Research” Vitamin B complex improves plastic and cosmetic surgery outcomes by enhancing tissue repair and reducing inflammation.
August 2024 in “Drug Design Development and Therapy” Decursin shows promise for treating cancer, neuroprotection, inflammation, and hair loss.
Nanocarriers with plant extracts show promise for safe and effective hair growth treatment.
January 2026 in “Aging and Disease” Targeting mitochondria can improve skin health and slow aging.
February 2024 in “Skin research and technology” The research suggests that immune cells and a specific type of cell death called ferroptosis are involved in Frontal fibrosis alopecia.
November 2023 in “IntechOpen eBooks” Arsenic exposure from contaminated water severely damages the skin, causing hair loss, pigmentation changes, irritation, and can lead to skin cancer.
March 2026 in “Journal of Enzyme Inhibition and Medicinal Chemistry” PROTACs show promise in cancer treatment by effectively degrading specific harmful proteins.
7 citations
,
March 2018 in “Experimental Dermatology” Acne lesions don't show increased keratinocyte growth compared to healthy hair follicles.
23 citations
,
December 2013 in “Molecular cancer therapeutics” Breast cancer treatments work better with AR activation, improving results and reducing side effects.
December 2025 in “npj Breast Cancer” Capivasertib improves survival in certain breast cancer cases but requires careful management of side effects.
September 2002 in “Oncology Times” Promising cancer treatments were found, but the manufacturer closed.
1 citations
,
January 2013 in “MedChemComm” PF-05314882 selectively activates androgen receptors without much effect on prostate and may help in prostate cancer treatment and hair loss prevention.
45 citations
,
July 2025 in “Journal of Medicinal Chemistry” Vepdegestrant may become the first FDA-approved PROTAC degrader, marking a new era in drug development.
80 citations
,
April 2017 in “Frontiers in Pharmacology” PDRN helps repair tissue and improve wound healing with a high safety profile.
1 citations
,
November 2022 in “Journal of Investigative Dermatology” ALRN-6924 may prevent hair loss caused by chemotherapy.
January 2024 in “Journal of dermatology and skin science” Topical aprepitant reduces skin rash and hair loss caused by cancer treatment.
February 2024 in “Cancers” New treatments targeting androgen receptors show promise for drug-resistant prostate cancer.
2 citations
,
December 2013 in “Cancer research” Enobosarm may effectively treat androgen receptor-positive breast cancer with fewer side effects.
18 citations
,
December 2016 in “European journal of pharmacology” A new compound slows cancer cell growth and causes cell death by blocking cell cycle progression and increasing cell-damaging molecules.
136 citations
,
April 2013 in “Clinical Cancer Research” The drug IPI-926 is safe at 160 mg daily and may help treat certain tumors, especially basal cell carcinoma.
July 2024 in “Journal of Investigative Dermatology” PH-762 shows promise in treating skin cancer by effectively targeting and silencing PD-1 in tumors with minimal side effects.
7 citations
,
September 2003 in “Journal of Investigative Dermatology” PAR-1 may play a role in hair growth regulation in human hair follicles.
June 2024 in “Journal of Clinical Oncology” Dalpiciclib is the safest and most satisfying CDK4/6 inhibitor for advanced breast cancer patients in China.